PMC:7558333 / 19835-21095 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T111","span":{"begin":189,"end":202},"obj":"Disease"}],"attributes":[{"id":"A111","pred":"mondo_id","subj":"T111","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"}],"text":"Supplementary Materials\nThe following are available online at https://www.mdpi.com/2309-608X/6/3/105/s1, Table S1: Clinical and biological features of the 9 patients classified as putative aspergillosis according to Blot et al., 2012.\nClick here for additional data file.\n\nAuthor Contributions\nConceptualization, J.-P.G., F.R., H.G., J.-M.T. and F.R.-G.; Data curation, J.-P.G., H.G., R.P., M.L. and F.R.-G.; Formal analysis, J.-P.G., F.R., H.G., M.L., J.-M.T. and F.R.-G.; Investigation, J.-P.G., F.R., H.G., K.P., P.L.B., R.P., E.P., S.B., M.L.S., Y.L.T., P.S., M.L. and J.-M.T.; Methodology, J.-P.G., F.R., H.G.and F.R.-G.; Project administration, J.-P.G.; Resources, J.-P.G, F.R., H.G., K.P., P.L.B., R.P., E.P., S.B., M.L.S., Y.L.T., P.S., M.L., J.-M.T. and F.R.-G.; Software, F.R.; Supervision, J.-P.G. and F.R.-G.; Validation, J.-P.G., Y.L.T. and F.R.-G.; Writing—original draft, J.-P.G. and F.R.-G.; Writing—review \u0026 editing, F.R., H.G. and J.-M.T. All authors have read and agreed to the published version of the manuscript.\n\nFunding\nThis research received no external funding.\n\nConflicts of Interest\nJ.-P.G. received funds for communications and congress attendance from Pfizer and Gilead. The other authors declare they have no conflict of interest."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T144","span":{"begin":101,"end":103},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"},{"id":"T145","span":{"begin":111,"end":113},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"}],"text":"Supplementary Materials\nThe following are available online at https://www.mdpi.com/2309-608X/6/3/105/s1, Table S1: Clinical and biological features of the 9 patients classified as putative aspergillosis according to Blot et al., 2012.\nClick here for additional data file.\n\nAuthor Contributions\nConceptualization, J.-P.G., F.R., H.G., J.-M.T. and F.R.-G.; Data curation, J.-P.G., H.G., R.P., M.L. and F.R.-G.; Formal analysis, J.-P.G., F.R., H.G., M.L., J.-M.T. and F.R.-G.; Investigation, J.-P.G., F.R., H.G., K.P., P.L.B., R.P., E.P., S.B., M.L.S., Y.L.T., P.S., M.L. and J.-M.T.; Methodology, J.-P.G., F.R., H.G.and F.R.-G.; Project administration, J.-P.G.; Resources, J.-P.G, F.R., H.G., K.P., P.L.B., R.P., E.P., S.B., M.L.S., Y.L.T., P.S., M.L., J.-M.T. and F.R.-G.; Software, F.R.; Supervision, J.-P.G. and F.R.-G.; Validation, J.-P.G., Y.L.T. and F.R.-G.; Writing—original draft, J.-P.G. and F.R.-G.; Writing—review \u0026 editing, F.R., H.G. and J.-M.T. All authors have read and agreed to the published version of the manuscript.\n\nFunding\nThis research received no external funding.\n\nConflicts of Interest\nJ.-P.G. received funds for communications and congress attendance from Pfizer and Gilead. The other authors declare they have no conflict of interest."}

{"project":"LitCovid-sentences","denotations":[{"id":"T140","span":{"begin":0,"end":23},"obj":"Sentence"},{"id":"T141","span":{"begin":24,"end":114},"obj":"Sentence"},{"id":"T142","span":{"begin":115,"end":234},"obj":"Sentence"},{"id":"T143","span":{"begin":235,"end":271},"obj":"Sentence"},{"id":"T144","span":{"begin":273,"end":293},"obj":"Sentence"},{"id":"T145","span":{"begin":294,"end":956},"obj":"Sentence"},{"id":"T146","span":{"begin":957,"end":1033},"obj":"Sentence"},{"id":"T147","span":{"begin":1035,"end":1042},"obj":"Sentence"},{"id":"T148","span":{"begin":1043,"end":1086},"obj":"Sentence"},{"id":"T149","span":{"begin":1088,"end":1109},"obj":"Sentence"},{"id":"T150","span":{"begin":1110,"end":1199},"obj":"Sentence"},{"id":"T151","span":{"begin":1200,"end":1260},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Supplementary Materials\nThe following are available online at https://www.mdpi.com/2309-608X/6/3/105/s1, Table S1: Clinical and biological features of the 9 patients classified as putative aspergillosis according to Blot et al., 2012.\nClick here for additional data file.\n\nAuthor Contributions\nConceptualization, J.-P.G., F.R., H.G., J.-M.T. and F.R.-G.; Data curation, J.-P.G., H.G., R.P., M.L. and F.R.-G.; Formal analysis, J.-P.G., F.R., H.G., M.L., J.-M.T. and F.R.-G.; Investigation, J.-P.G., F.R., H.G., K.P., P.L.B., R.P., E.P., S.B., M.L.S., Y.L.T., P.S., M.L. and J.-M.T.; Methodology, J.-P.G., F.R., H.G.and F.R.-G.; Project administration, J.-P.G.; Resources, J.-P.G, F.R., H.G., K.P., P.L.B., R.P., E.P., S.B., M.L.S., Y.L.T., P.S., M.L., J.-M.T. and F.R.-G.; Software, F.R.; Supervision, J.-P.G. and F.R.-G.; Validation, J.-P.G., Y.L.T. and F.R.-G.; Writing—original draft, J.-P.G. and F.R.-G.; Writing—review \u0026 editing, F.R., H.G. and J.-M.T. All authors have read and agreed to the published version of the manuscript.\n\nFunding\nThis research received no external funding.\n\nConflicts of Interest\nJ.-P.G. received funds for communications and congress attendance from Pfizer and Gilead. The other authors declare they have no conflict of interest."}

{"project":"LitCovid-PubTator","denotations":[{"id":"440","span":{"begin":157,"end":165},"obj":"Species"},{"id":"441","span":{"begin":189,"end":202},"obj":"Disease"}],"attributes":[{"id":"A440","pred":"tao:has_database_id","subj":"440","obj":"Tax:9606"},{"id":"A441","pred":"tao:has_database_id","subj":"441","obj":"MESH:D001228"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Supplementary Materials\nThe following are available online at https://www.mdpi.com/2309-608X/6/3/105/s1, Table S1: Clinical and biological features of the 9 patients classified as putative aspergillosis according to Blot et al., 2012.\nClick here for additional data file.\n\nAuthor Contributions\nConceptualization, J.-P.G., F.R., H.G., J.-M.T. and F.R.-G.; Data curation, J.-P.G., H.G., R.P., M.L. and F.R.-G.; Formal analysis, J.-P.G., F.R., H.G., M.L., J.-M.T. and F.R.-G.; Investigation, J.-P.G., F.R., H.G., K.P., P.L.B., R.P., E.P., S.B., M.L.S., Y.L.T., P.S., M.L. and J.-M.T.; Methodology, J.-P.G., F.R., H.G.and F.R.-G.; Project administration, J.-P.G.; Resources, J.-P.G, F.R., H.G., K.P., P.L.B., R.P., E.P., S.B., M.L.S., Y.L.T., P.S., M.L., J.-M.T. and F.R.-G.; Software, F.R.; Supervision, J.-P.G. and F.R.-G.; Validation, J.-P.G., Y.L.T. and F.R.-G.; Writing—original draft, J.-P.G. and F.R.-G.; Writing—review \u0026 editing, F.R., H.G. and J.-M.T. All authors have read and agreed to the published version of the manuscript.\n\nFunding\nThis research received no external funding.\n\nConflicts of Interest\nJ.-P.G. received funds for communications and congress attendance from Pfizer and Gilead. The other authors declare they have no conflict of interest."}